FDA approves first biosimilar for cancer, including mRCC
The FDA has approved MVASI (bevacizumab-awwb) for all eligible indications of the reference product, Avastin (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA, according to a joint statement from Amgen and Allergan plc. MVASI is approved for the treatment of five types of cancer, including metastatic renal cell carcinoma in combination with interferon alfa. MVASI is a biosimilar to bevacizumab, a recombinant immunoglobulin G1 monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 and VEGF receptor-2, thus inhibiting establishment of new blood vessels necessary for the maintenance and growth of solid tumors.
For more information, go to www.amgen.com/.